Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: Results of cancer and leukemia group B 99811

Cancer

Volumn 113, Issue 11, 2008, Pages 3137-3145

  Kelly, William Kevin ^a   Halabi, Susan ^b   Elfiky, Aymen ^a   Ou, San San ^c   Bogart, Jeff ^d   Zelefsky, Michael ^e   Small, Eric ^f  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d State University of New York Upstate Medical University: College of Medicine   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgen deprivation; Chemotherapy (paclitaxel, estramustine, carboplatin); Radiotherapy; Unfavorable risk localized prostate cancer

Indexed keywords

ANTIANDROGEN; ANTINEOPLASTIC AGENT; CARBOPLATIN; ESTRAMUSTINE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN;

ADJUVANT THERAPY; AGED; ARTICLE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; FEASIBILITY STUDY; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; PROSTATE TUMOR;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ESTRAMUSTINE; FEASIBILITY STUDIES; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 58149379293     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23910     Document Type: Article

References (23)

1. Mettlin CJ, Murphy GP, Rosenthal DS, Menck HR. The National Cancer Data Base report on prostate carcinoma after the peak incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83:1679.
2. Newling DW, Dennis L, Vermeylen K. Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer-Genitourinary Group Study 30853. Cancer 1993;72(12 suppl):3793-3798. (Pubitemid 23361529)
3. Lerner SE, Blute ML, Zincke H. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol. 1995;154:1447.
4. van den Ouden D, Hop WCJ, Schroder FH. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol. 1998;160:1392.
5. Zagars GK, von Eschenbach AC, Ayala AG. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy. Cancer. 1993;72:1709.
6. Zietman AL, Coen JJ, Dallow KC, Shipley WU. The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int J Radiat Oncol Biol Phys. 1995;32:287.
7. D'Amico AV, Moul JW, Kattan MW. Emerging prognostic factors for outcome prediction in clinically localized prostate cancer: prostate-specific antigen level, race, molecular markers and neural networks. In: Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS, eds. Genitourinary Oncology, 2nd ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2000:681-697.
8. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical retropubic prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am. 1993;20:713.
9. Soloway MS, Sharifi R, Wajsman Z, et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy proceeded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol. 1995;154:424.
10. Goldenberg SL, Klotz LH, Srigley J, et al. Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. J Urol. 1996;156:873.
11. Pilepich MV, Krall JM, al-Sarraf M, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. Urology. 1995;45:616-623.
12. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295-300.
13. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of the Radiation Therapy Oncology Group protocol 85-31. J Clin Oncol. 1997;15:1013-1021. (Pubitemid 27106285)
14. Zelefsky MJ, Kelly WK, Scher HI, et al. Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose 3-dimensional conformal radiotherapy for patients with locally advanced prostate cancer. J Clin Oncol. 2000;18:1936.
15. Kelly WK, Curley T, Slovin S, et al. Paclitaxel, estramustine phosphate and carboplatin (TEC) in patients with advanced prostate cancer. J Clin Oncol. 2001;19:44-53. (Pubitemid 32063478)
16. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097-1105. (Pubitemid 34787842)
17. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003;21:3972-3978. (Pubitemid 46606211)
18. Lawton CA, DeSilvio M, Roach M III. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. 2007;69:646-655. (Pubitemid 47418390)
19. Khil MS, Kim JH, Bricker LJ, Cerny JC. Tumor control of locally advanced prostate cancer following combined estramustine, vinblastine, and radiotherapy. Cancer J Sci Am. 1997;3:289-296.
20. Ben-Josef E, Porter AT, Han S, et al. Neoadjuvant estramustine and etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer: feasibility and preliminary results. Int J Radiat Oncol Biol Phys. 2001;49:699-703. (Pubitemid 32114104)
21. Hussain M, Smith DC, El-Rayes BF, et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. Urology. 2003;61:774-780. (Pubitemid 36384972)
22. Kumar P, Perrotti M,Weiss R, et al. Phase I trial of weekly docetaxel with concurrent 3-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate. J Clin Oncol. 2004;22:1909-1915. (Pubitemid 41095183)
23. Sandler HM, DeSilvio M, Pienta K, et al. Preliminary analysis of RTOG 9902: increased toxicity observed with the use of adjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2005;63:S123.